Latest news with #Wockhardt
Economic Times
5 days ago
- Business
- Economic Times
Wockhardt shares jump 17%, hit fresh 52-week high
Live Events (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel Shares of Wockhardt surged 17% to hit their 52-week high of Rs 1,809 on the NSE. The stock has extended its unbeaten streak to the third session in a row. The stock garnered strong interest from the investors with a spurt in volume of more than 4.5 times on the stock gained amid buying action in the pharma pack, with Nifty among the top-performing sectors in a lacklustre trade today. The Nifty Bank was up 0.4% with 14 stocks trading in the green in the 20-stock pharma company, which is into branded manufacturing of drugs, contract manufacturing, API and vaccines, released its forward-looking statements last week on company said that it has filed for its Zaynich drug with the Drug Controller General of India (DCGI) for approval, and the India launch is expected in H2 FY25- company recently reported fourth quarter results for the financial year 2024-25. The company's revenue for Q4FY25 stood at Rs 743 crore compared to Rs 750 crore in the previous year. The Earnings Before Interest, Taxes, Depreciation and Amortisation (EBITDA) grew 13% QoQ in the quarter under review at Rs 79 crore compared to Rs 70 crore in the previous company's net losses in the January-March quarter of FY25 narrowed to Rs 45 crore versus Rs 177 crore in the year-ago period. The PAT margins were reported at -6.1% versus -23.6% versus those in the year-ago company reported 7 filings for new product launches in FY2024- 25 and 6 launches in Wockhardt UK, along with 1 filing and 6 new launches in the biosimilars & NCE segments, 19 filings & 5 approvals were India-branded business stood at Rs 95 crore in Q4FY25, and for FY25, the revenue was Rs 456 crore. The UK Business stood at Rs 292 crore in Q4FY25 with a growth of 9%, and for FY25, the revenue was Rs 1,169 crore with a growth of 12%. Meanwhile, the Irish Business stood at Rs 47 crore in Q4FY2,5 and for FY25, the revenue was Rs 181 crore.
Time of India
5 days ago
- Business
- Time of India
Wockhardt shares jump 17%, hit fresh 52-week high
Wockhardt extended its winning streak for the third straight session, drawing strong investor interest with trading volumes surging over 4.5 times on the BSE. The stock rallied alongside broader buying momentum in the pharma sector. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Shares of Wockhardt surged 17% to hit their 52-week high of Rs 1,809 on the NSE. The stock has extended its unbeaten streak to the third session in a row. The stock garnered strong interest from the investors with a spurt in volume of more than 4.5 times on the stock gained amid buying action in the pharma pack, with Nifty among the top-performing sectors in a lacklustre trade today. The Nifty Bank was up 0.4% with 14 stocks trading in the green in the 20-stock pharma company, which is into branded manufacturing of drugs, contract manufacturing, API and vaccines, released its forward-looking statements last week on company said that it has filed for its Zaynich drug with the Drug Controller General of India (DCGI) for approval, and the India launch is expected in H2 FY25- company recently reported fourth quarter results for the financial year 2024-25. The company's revenue for Q4FY25 stood at Rs 743 crore compared to Rs 750 crore in the previous year. The Earnings Before Interest, Taxes, Depreciation and Amortisation (EBITDA) grew 13% QoQ in the quarter under review at Rs 79 crore compared to Rs 70 crore in the previous company's net losses in the January-March quarter of FY25 narrowed to Rs 45 crore versus Rs 177 crore in the year-ago period. The PAT margins were reported at -6.1% versus -23.6% versus those in the year-ago company reported 7 filings for new product launches in FY2024- 25 and 6 launches in Wockhardt UK, along with 1 filing and 6 new launches in the biosimilars & NCE segments, 19 filings & 5 approvals were India-branded business stood at Rs 95 crore in Q4FY25, and for FY25, the revenue was Rs 456 crore. The UK Business stood at Rs 292 crore in Q4FY25 with a growth of 9%, and for FY25, the revenue was Rs 1,169 crore with a growth of 12%. Meanwhile, the Irish Business stood at Rs 47 crore in Q4FY2,5 and for FY25, the revenue was Rs 181 crore.
&w=3840&q=100)
Business Standard
5 days ago
- Business
- Business Standard
Rekha Jhunjhunwala portfolio stock soars 17%; zooms over 950% in 2 years
Wockhardt share price today: Shares of pharmaceutical company Wockhardt hit an all-time high of ₹1,809.95, as they rallied 17 per cent on the BSE in Wednesday's intra-day trade amid heavy volumes on healthy business outlook. The stock price of this smallcap pharmaceutical company surpassed its previous high of ₹1,678.60, which it had touched on February 6, 2025. In the past one month, Wockhardt has outperformed the market by surging 47 per cent, as compared to 0.3 per cent rise in the BSE Sensex. Further, in the past year, the stock zoomed 206 per cent, as against 8 per cent gain in the benchmark index. The stock price of Wockhardt has skyrocketed 956 per cent from level of ₹171.45 on the BSE. At 12:36 PM; the stock was quoting 16 per cent higher at ₹1,802.40, as against 0.33 per cent gain in the BSE Sensex. The average trading volumes on the counter jumped three-fold. A combined 4.34 million shares have changed hands on the NSE and BSE. Rekha Jhunjhunwala held over 1 per cent holding in Wockhardt Ace investor Rekha Jhunjhunwala held 2.84 million shares representing 1.75 per cent stake in Wockhardt at the end of March 31, 2025, the shareholding pattern data shows. Strong FY25 results Wockhardt had reported a strong operational performance with 67 per cent year-on-year (Y-o-Y) growth in earnings before interest, taxes, depreciation, and amortisation (Ebitda) at ₹418 crore for the financial year 2024-25 (FY25) compared to ₹251 crore in the previous year (FY24). Ebitda margin improved to 13.8 per cent, from 8.7 per cent. Revenue, however, grew 5 per cent Y-o-Y to ₹3,033 crore in FY25, compared to ₹2,879 crore in FY24. For FY25, the company said its net loss stood at ₹57 crore as compared to ₹472 crore in the year-ago period. Zaynich: Planned for filing in USA by August 2025 Following the completion of the Global, pivotal, registration-enabling, Phase III study in hospitalised complicated urinary tract infection (cUTI) patients, Wockhardt's Zaynich has demonstrated the highest-ever efficacy achieving a clinical cure rate of 96.8 per cent. Wockhardt, while announcing Q4 results on May 29, 2025, said that this study is NDA-enabling, based on which marketing authorisation applications will be made to global health authorities including India, US, EMA and MHRA. For India, the Drug Controller General of India (DCGI) filing for commercial approval was submitted on March 31, 2025. In parallel, preparations for the US New Drug Application (NDA) filings are progressing, marked by the successful completion of a pre-NDA meeting with the US Food and Drug Administration (FDA). Filing in the USA is expected by August 2025, the company said. Meanwhile, Wockhardt, which is all set to launch its new class of antibiotic Zaynich targeted at treating complicated gram-negative infections in India this year, estimates that the drug would have an addressable market of $7 billion in the US and Europe, besides a ₹17,000 crore opportunity in India, taking the total opportunity to $9 billion. The company is expecting to get a nod from the DCGI soon. It hopes for a launch in the second half of this financial year. In an investor presentation, Wockhardt said that it had completed the pre-ANDA meeting with the US Food and Drug Administration (USFDA) in May and is filing with the regulator in Q2FY26, expecting a potential launch in the financial year 2026-27 (FY27). It aims to file for approval in the European Union (EU) and emerging markets in H2FY26. Apart from Zaynich, Wockhardt is pinning its hopes on other drugs in its antibiotic portfolio (like Miqnaf or Nafithromycin), and its biotechnology portfolio including insulins. Miqnaf is targeting a ₹10,800 crore market opportunity in India with over 96 million potential prescriptions. About Wockhardt Wockhardt is a research based Global Pharmaceutical and Biotech company. Wockhardt's New Drug Discovery programme has focussed on the unmet need of Anti-bacterial drugs that are effective against the menace of untreatable superbugs. Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified Infectious Disease Product) for 6 of its Anti-bacterial discovery programmes – 3 of them are Gram Negative and 3 Gram Positive effective against untreatable 'Superbugs'. It has a comprehensive Drug Discovery team and clinical organisation. Wockhardt has a significant presence in the USA, Europe and India, with 77 per cent of its global revenues coming from international businesses.
Hans India
06-06-2025
- Business
- Hans India
Wockhardt eyes $7 bn mkt opp for antibiotic Zaynich
New Delhi: Drugmaker Wockhardt said its novel antibiotic Zaynich has an addressable market opportunity of $7 billion in the US and Europe. The company said it has completed a pre-NDA (non-disclosure agreement) meeting with the US Food and Drug Administration (USFDA) in May 2025. Filing to the USFDA is slated in the second quarter of the current fiscal with potential launch in FY2026-27, Wockhardt Ltd said in a regulatory filing. The company plans for regulatory approval for the product in Europe and emerging markets in the second half of the current financial year, it added. Wockhardt said it has also filed for approval of Zaynich with the Drug Controller General of India (DCGI) and expects to launch the product in the domestic market in the second half of the current fiscal. The antibiotic, to be used against gram-negative infections, is expected to help 11 lakh cases in India alone, the Mumbai-based drug maker said.
&w=3840&q=100)
Business Standard
05-06-2025
- Business
- Business Standard
Wockhardt eyes $9 bn market opportunity for novel antibiotic Zaynich
Mumbai-based pharmaceutical major Wockhardt, which is set to launch a new class of antibiotic, Zaynich, in India this year, estimates a total addressable market opportunity of $9 billion. This includes a $7-billion market in the US and Europe, and a ₹17,000-crore opportunity in India. The company's stock rose 2.4 per cent on the BSE on Thursday following an investor presentation outlining its growth plans for the next three to five years. Zaynich (or WCK 5222) is a key research candidate in Wockhardt's pipeline. It has completed global Phase 3 clinical trials, demonstrating a 20 per cent higher (statistically superior) composite cure rate compared to Meropenem, the current gold standard in antibiotics. Wockhardt claims Zaynich is the first new class of antibiotic in over 30 years to treat gram-negative infections. The drug has already saved 51 lives under compassionate use, including three in the US, where patients had failed all existing therapies. Zaynich is indicated for complicated urinary tract infections (UTIs), hospital-acquired and ventilator-associated bacterial pneumonia, bloodstream infections, and complicated intra-abdominal infections. The company expects approval from the Drugs Controller General of India (DCGI) shortly and plans to launch the drug in the second half of this financial year. Wockhardt has completed a pre-NDA (New Drug Application) meeting with the US Food and Drug Administration (USFDA) in May and plans to file in Q2FY26, targeting a potential launch in FY27. Regulatory filings in the EU and emerging markets are scheduled for the second half of FY26. Wockhardt estimates that around 1.1 million patients in India may benefit from Zaynich, while 371,000 carbapenem-resistant cases in the US and Europe are potential candidates. Overall, there are 4.3 million hospitalised cases involving key gram-negative pathogens in the US and EU. The firm sees a combined addressable patient pool of 2 million across India, the US, Europe, and China. Apart from Zaynich, Wockhardt is also betting on other antibiotics in its portfolio, such as Miqnaf (Nafithromycin), and its biotechnology portfolio, including insulin products. Miqnaf, already launched in India, treats community-acquired bacterial pneumonia (CABP) and upper respiratory tract infections. It has received Qualified Infectious Disease Product (QIDP) status from the USFDA, signifying unmet medical need, and Breakthrough Medicinal Product (BMP) designation in Saudi Arabia. Miqnaf targets a ₹10,800-crore market in India, with over 96 million potential prescriptions. In the biosimilars segment, Wockhardt is focusing on diabetes care and sees significant opportunity arising as Danish major Novo Nordisk phases out human insulin cartridges. This creates a ₹450-crore opportunity in India and a $157-million market across emerging economies. With only three major players in India, including itself, Wockhardt expects to benefit substantially. The company is doubling its diabetes biosimilars capacity over the next three years to meet growing demand, targeting business growth of 20–25 per cent.
